MorphoSys Announces Clinical Milestone in Ophthalmology Program
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Clinical Milestone in Ophthalmology Program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that it has received a milestone payment from Novartis in connection with
the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of
diabetic eye diseases. This becomes the ninth therapeutic antibody made using
MorphoSys's technologies that Novartis is evaluating in clinical trials.
The official start of the clinical trial, which will be conducted in research
centers in Australia, is pending final approval by regulatory authorities there.
"The clinical output of our strategic alliance with Novartis has been remarkable
so far. We are looking forward to seeing more programs with Novartis moving into
the clinic in the months and years ahead," commented Dr. Marlies Sproll, Chief
Scientific Officer of MorphoSys AG. "We are also very pleased that this is the
third ophthalmology program within our collaboration to enter the clinical
development stage."
MorphoSys's collaboration with Novartis has resulted in nine clinical programs
to date, four of which are in Phase 1 development, with another four programs in
Phase 2 and one in Phase 3. In total, MorphoSys's partnered and proprietary
clinical pipeline currently comprises 21 unique antibody molecules which are
being evaluated in more than 50 clinical trials.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 80 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®)
and Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Specialist Corporate Communications & IR
Jessica Rush
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release:
http://hugin.info/130295/R/1863829/654010.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1863829]
Unternehmensinformation / Kurzprofil:
Datum: 20.10.2014 - 07:30 Uhr
Sprache: Deutsch
News-ID 345116
Anzahl Zeichen: 4701
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Clinical Milestone in Ophthalmology Program"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
